Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Post-vaccination SARS-CoV-2 infection among healthcare workers in tertiary care hospitals in Saudi Arabia: A case series

Majid M. Alshamrani a, b, c, *, Fayssal M Farahat a, b, c, Aiman El-Saied a, b, c, Mohammed Alzunitan a, b, c, Asim Alsaedi b, c, d, Ayman El Gammal e, Wafaa Al Nasser f, Syed Nazeer g, Saad A. Almohri h

1 Infection Prevention and Control Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2 King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia
3 King Abdullah International Medical Research Center, Saudi Arabia
4 Infection Prevention and Control Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
5 Infection Prevention and Control Department, King Abdulaziz Hospital, Ministry of National Guard Health Affairs, Alhasa, Saudi Arabia
6 Infection Prevention and Control Department, Imam Abdulrahman Bin Faisal Hospital, Ministry of National Guard Health Affairs, Dammam, Saudi Arabia
7 Infection Prevention and Control Department, Prince Mohammed Bin Abdul Aziz Hospital, Al Madinah, Saudi Arabia
8 Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Saudi Arabia

ARTICLE INFO
Article history:
Received 31 May 2021
Received in revised form 23 October 2021
Accepted 15 November 2021

Keywords:
Coronavirus disease (COVID-19)
Pandemic
Hospital
Healthcare
Saudi Arabia

ABSTRACT
Healthcare workers have been categorized among the priority groups for COVID-19 vaccination. However, post-vaccination infections have been identified. This study was conducted to investigate SARS-CoV-2 infection among healthcare workers (HCWs) who received the COVID-19 vaccine. A case series in a multicenter healthcare system in Saudi Arabia was created from HCWs who had (PCR-RT) confirmed SARS-CoV-2 infection after at least one dose of Pfizer-BioNTech vaccination. A total of 20 healthcare workers (HCWs) have been included. The majority (70.0%) were males and the average age was 39.4 ± 10.1 years. They included physicians (55.0%), nurses (25.0%) and other HCWs (20.0%). Eighteen (90%) HCWs had infection after the first dose; 47.1% within the first week, 41.2% within the second week, and 11.8% within the third week. Only two HCWs (10.0%) had infection one week after the second dose. The majority (63.2%) had mild (52.6%) or moderate (10.3%) disease with no severe disease or hospitalization. The majority of post-vaccination COVID-19 infections among HCWs occurred before the full protection of the vaccine is gained. Suspicion of COVID-19 infection should be considered even with a history of COVID-19 vaccination. Recently vaccinated HCWs should be advised to fully comply with all recommended precautions to prevent COVID-19 transmission.

© 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background
The current coronavirus disease (COVID-19) pandemic is considered a huge burden for healthcare workers (HCWs), both physically and mentally [1]. They suffer from a considerably higher risk of exposure to and infection with SARS-CoV-2 compared with the general population [2,3]. The WHO, the Centers for Disease Control and Prevention (CDC), and the Ministries of Health identified HCWs as a priority for COVID-19 vaccination even during the period of initial limited supply [4,5].

In Saudi Arabia, a COVID-19 vaccination campaign was started on the last week of December 2020, following approval of the Pfizer-BioNTech vaccine by the Saudi Food and Drug Administration (SFDA) [6]. Although Pfizer-BioNTech reported a high safety and efficacy vaccine profile [7], there have been some initial concerns among the population in Saudi Arabia including HCWs [8]. The current study was conducted to investigate post-vaccination SARS-CoV-2 infection among HCWs who received the Pfizer-BioNTech vaccine in a multihospital healthcare system in Saudi Arabia.

* Corresponding author at: Adult Infectious Disease, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Riyadh 11426, Saudi Arabia.
E-mail addresses: Alshamranim2@ngha.med.sa, Drshomrani@yahoo.com (M.M. Alshamrani).

https://doi.org/10.1016/j.jiph.2021.11.015
1876-0341/© 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The current study was conducted at the six Ministry of National Guard Health Affairs (MNGHA) hospitals in Riyadh, Jeddah, Alahsa, Dammam, and Madinah. MNGHA hospitals are tertiary care governmental hospitals with a total of 2510 beds. They provide healthcare services for Saudi National Guard soldiers, employees, and their families. MNGHA hospitals are served by 19,016 clinical HCWs; including 4605 physicians, 8701 nurses, and 5710 other clinical HCWs.

A case series study has been conducted based on prospective surveillance among HCWs who were working in MNGHA hospitals during the study period and had confirmed SARS-CoV-2 infection after COVID-19 vaccination. The duration covered was three months (from December 24, 2020, to March 23, 2021).

HCWs who had a positive RT-PCR test for COVID-19, irrespective of the presence of symptoms were identified. Data were collected on the HCW’s demographics, symptoms, exposure, and vaccination history.

Descriptive statistics were done using SPSS software (Version 22.0, Armonk, NY: IBM Corp.).

The majority (63.2%) of the HCWs who reported clinical symptoms had either mild (52.6%) or moderate (10.5%) disease while 36.8% of the HCWs had asymptomatic disease. The most frequent symptoms included fever (36.8%), cough (36.8%), headache (21.1%), malaise (21.1%), sore throat (21.1%), runny nose (15.8%), and shortness of breath (10.5%). All HCWs were isolated in the home and required no hospital admission. The majority (65.0%) of HCWs could not recognize COVID-19 exposure with only 35.0% reported COVID-19 exposure related to the workplace (15.0%), family (15.0%), and community (5.0%). Moreover, no reports of COVID-19 clusters linked to the immunization process have been identified.

Discussion

In the current report, 20 HCWs with post-vaccination laboratory-confirmed SARS-CoV-2 infection were investigated. The majority (90%) had SARS-CoV-2 infection before the vaccine full protection is reached. Consistent with current findings, data published at the time of the study (early 2021) showed that 91%–96% of post-vaccination infections occurred before full protection, at least one week after the second dose [7,9].
The frequency of post-vaccination infection in this case series was decreasing as the duration from the first dose was increasing, indicating mounting protection. Consistent with these findings, an interim analysis of Pfizer-BioNTech vaccination data after excluding those who got the infection in the first two weeks after the first dose showed increased vaccine efficacy from 89% to 91% during the period between 15 and 28 days after the first dose [10].

A the time of this study, the original alpha variant was predominant. Over time an increased concern of surge of cases coinciding with the spread of other variants (i.e., beta and delta) has been raised globally. A test-negative case-control study in the UK showed modest differences in vaccine effectiveness against symptomatic disease with delta compared to the alpha variant [11]. Additionally, another case-control study among healthcare workers argued the role of initial immune response compared to the decay of antibody levels on the degree of protection against breakthrough infections [12].

Despite being among the first case series about post-vaccination COVID-19 in Saudi Arabia and the region, a couple of limitations should be acknowledged. As HCWs were vaccinated in centers outside the MNGHA hospital authority, the total number of vaccinated HCWs in MNGHA hospitals could not be obtained. This hindered our ability to estimate the vaccine effectiveness. Additionally, PCR testing after vaccination was based on self-request. Therefore, HCWs who got asymptomatic disease may pass unnoticed if testing was not sought. However, this most probably cannot be avoided in similar studies.

In conclusion, the current report reconfirms the possibility of post-vaccination COVID-19 infection among HCWs. The false sense of full protection immediately following vaccination might have increased undue exposure while adherence to precautionary measures was inconsistently followed. Efforts should be maintained to ensure completion of the recommended vaccine series among the general population, with special emphasis on the high-risk people including HCWs. Strategies that include sequencing of viral RNA and monitoring of neutralizing antibody titers, particularly in persons with breakthrough infection should continue to identify pandemic change and determine the effectiveness of the applied interventions.

**Funding**

No funding sources.

**Competing interests**

None declared.

**Ethical approval**

Not required.

**Author contributions**

**Majid M. Alshamrani:** Conception, Design, Acquisition of data, Analysis and interpretation of data; **Fayssal M. Farahat:** Conception, Design, Acquisition of data, Analysis and interpretation of data; **Aiman El-Saad:** Conception, Design, Acquisition of data, Analysis and interpretation of data; **Mohammed Alzunitani:** Acquisition of data and interpretation of data; **Asim Alsaedi:** Acquisition of data and interpretation of data; **Ayman El Gammal:** Acquisition of data and interpretation of data; **Wafaa Al Nasser:** Acquisition of data and interpretation of data; **Syed Nazeer:** Acquisition of data and interpretation of data; **Saad A Almohri:** Conception and interpretation of data.

**References**

[1] Cabarkapa S, Nadijadai SE, Murgier J, Ng CH. The psychological impact of COVID-19 and other viral epidemics on frontline healthcare workers and ways to address it: a rapid systematic review. Brain Behavior Immunity 2020;8. http://dx.doi.org/10.1016/j.bbi.2020.100144.

[2] Wei Jie, Liu ZD, Fan ZW, Zhao L, Cao WC. Epidemiology of and risk factors for COVID-19 infection among healthcare workers: a multi-centre comparative study. Int J Environ Res Public Health 2020;17, http://dx.doi.org/10.3390/ijerph1719149.

[3] Alserehi HA, Alquaiabi AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN, Alanazi KH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagn Microbiol Infect Dis 2021;99(3):115273, http://dx.doi.org/10.1016/j.diagmicrobio.2020.115273.

[4] World Health Organization. WHO sage roadmap for prioritizing uses of Covid-19 vaccines in the context of limited supply. WHO; 2020.

[5] Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The advisory committee on immunization practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine — united states, 2020. MMWR Morb Mortal Wkly Rep 2020;69(49):1857–9, http://dx.doi.org/10.15585/mmwr.mm6949e1.

[6] Saudi Ministry of Health. Al-Rabiah launches COVID-19 vaccination campaign; 2021 https://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/News-2020-12-17-007.aspx.

[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020;383(27):2603–15, http://dx.doi.org/10.1056/nejmoa2034577.

[8] Qattan AMN, Alshareef N, Alshariq O, Al Rahaleh N, Chirwa GC, et al. Acceptability of a COVID-19 vaccine among healthcare workers in the Kingdom of Saudi Arabia. Front Med 2021;8, http://dx.doi.org/10.3389/fmed.2021.644390.

[9] Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med 2021;384, http://dx.doi.org/10.1056/nejmc2101927.

[10] Public Health England. Annex A: Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222); 2021 https://assets.publishing.service.gov.uk/Government/uploads/system/uploads/attachment_data/file/949505/Annex-a-The-Report-to-JCVI-on-Estimated-Efficacy-of-Single-Vaccine-DosePdf.pdf.

[11] Lopez Bernal J, Andrews N, Gover C, Gallagher E, Simmons R, Theelwall S, et al. Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021;385, http://dx.doi.org/10.1056/nejmoa2108891.

[12] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385(16):1474–84, http://dx.doi.org/10.1056/nejmoa2109072.